NCT01613820.

Study name	Combination of anticholinergic and glutamatergic effects in treatment‐resistant major depressive disorder. A pilot study
Methods	We therefore plan to investigate the feasibility and efficacy of open‐label repeated intravenous administration of ketamine and scopolamine combined in this population of severely depressed, treatment‐resistant patients
Participants	Inclusion criteria Outpatients with sever treatment‐resistant depression Currently depressed Currently under regular psychiatric care On an aggressive antidepressant regimen, stable for 4 weeks Exclusion criteria No history of other major psychiatric illnesses, including bipolar disorder No history of psychosis No history of drug abuse No major medical illness or unstable medical condition.
Interventions	Ketaine + placebo, scopolamine + placebo, ketamine + scopolamine
Outcomes	Primary outcome measures: HRSD‐28. Time frame: up to 4 months. [Designated as safety issue: No]. Participants will be assessed with HRSD‐28
Starting date	September 2015
Contact information	Cristina Cusin, M.D., MGH Department of Psychiatry
Notes	NCT01613820